AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,545,000 | -37.5% | 150,000 | 0.0% | 0.36% | -33.1% |
| Q2 2023 | $2,472,000 | +59.4% | 150,000 | -11.8% | 0.54% | +51.7% |
| Q1 2023 | $1,551,250 | +30.4% | 170,000 | 0.0% | 0.36% | +28.5% |
| Q4 2022 | $1,190,000 | +49.7% | 170,000 | +9.0% | 0.28% | +57.4% |
| Q3 2022 | $795,000 | +108.7% | 156,000 | 0.0% | 0.18% | +114.6% |
| Q2 2022 | $381,000 | -61.5% | 156,000 | +7.6% | 0.08% | -57.9% |
| Q1 2022 | $990,000 | -15.5% | 145,000 | 0.0% | 0.20% | -8.9% |
| Q4 2021 | $1,172,000 | -17.5% | 145,000 | 0.0% | 0.21% | -22.7% |
| Q3 2021 | $1,421,000 | +61.3% | 145,000 | +11.5% | 0.28% | +54.7% |
| Q2 2021 | $881,000 | -25.0% | 130,000 | 0.0% | 0.18% | -28.4% |
| Q1 2021 | $1,175,000 | +73.0% | 130,000 | +30.0% | 0.25% | +62.3% |
| Q4 2020 | $679,000 | +124.8% | 100,000 | +66.7% | 0.15% | +120.0% |
| Q3 2020 | $302,000 | – | 60,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |